Heska to Present at J.P. Morgan 2019 Healthcare Conference

LOVELAND, Colo., Jan. 4, 2019 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA - News; "Heska" or the "Company"), a provider of advanced veterinary diagnostic and specialty products, announced that Kevin Wilson, Heska's President & Chief Executive Officer, will present at the J.P. Morgan 2019 Healthcare Conference on Thursday, January 10, 2019 at 11 a.m. PT in San Francisco, CA.

Management will be available for one-on-one meetings on January 10^th.  To schedule a meeting, please contact J.P. Morgan at [email protected] or Heska Investor Relations at [email protected].

A live webcast of the company's presentation can be accessed at https://jpmorgan.metameetings.net/events/healthcare19/sessions/25891-heska/webcast and a live webcast of the subsequent Question and Answer session can be accessed at https://jpmorgan.metameetings.net/events/healthcare19/sessions/25892-heska-q-a/webcast.

The webcast will be archived shortly after the event, and a replay will be available on the company's website for 90 days following the conference.  A copy of the presentation can be found on Heska's website at https://ir.heska.com/event/presentation/. 

For more information about the J.P. Morgan 2019 Healthcare Conference, visit:
https://www.jpmorgan.com/country/US/en/healthcareconference?source=cib_di_jp_hlthconfmos1218.

About Heska

Heska Corporation (NASDAQ: HSKA - News) manufactures, develops and sells advanced veterinary diagnostic and specialty healthcare products through two business segments; Core Companion Animal Health ("CCA") represents approximately 80% of revenues, and Other Vaccines, Pharmaceuticals and Products ("OVP") segment represents approximately 20% of revenues. CCA segment includes Point of Care Laboratory testing instruments and consumables, primarily under a unique multi-year Reset Subscription model, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings such as in-clinic diagnostic tests and heartworm preventive products. OVP segment includes private label vaccine and pharmaceutical production under third party agreements and channels, primarily for herd animal health. For further information on Heska and its products, visit www.heska.com.

SOURCE Heska Corporation

Related Links

http://www.heska.com